- Home
- SMSI vs GDTC Comparison
SMSI vs GDTC Comparison
Compare SMSI & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMSI
- GDTC
- Stock Information
- Founded
- SMSI 1982
- GDTC 2018
- Country
- SMSI United States
- GDTC Singapore
- Employees
- SMSI N/A
- GDTC N/A
- Industry
- SMSI Computer Software: Prepackaged Software
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- SMSI Technology
- GDTC Health Care
- Exchange
- SMSI Nasdaq
- GDTC Nasdaq
- Market Cap
- SMSI 24.7M
- GDTC 28.0M
- IPO Year
- SMSI 1995
- GDTC 2023
- Fundamental
- Price
- SMSI $0.97
- GDTC $2.22
- Analyst Decision
- SMSI Strong Buy
- GDTC Buy
- Analyst Count
- SMSI 1
- GDTC 1
- Target Price
- SMSI $5.00
- GDTC $5.00
- AVG Volume (30 Days)
- SMSI 142.6K
- GDTC 16.2K
- Earning Date
- SMSI 05-07-2025
- GDTC 01-01-0001
- Dividend Yield
- SMSI N/A
- GDTC N/A
- EPS Growth
- SMSI N/A
- GDTC N/A
- EPS
- SMSI N/A
- GDTC N/A
- Revenue
- SMSI $19,378,000.00
- GDTC $368,838.00
- Revenue This Year
- SMSI $36.40
- GDTC N/A
- Revenue Next Year
- SMSI $46.07
- GDTC N/A
- P/E Ratio
- SMSI N/A
- GDTC N/A
- Revenue Growth
- SMSI N/A
- GDTC 264.63
- 52 Week Low
- SMSI $0.52
- GDTC $1.20
- 52 Week High
- SMSI $2.90
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- SMSI 50.16
- GDTC 42.78
- Support Level
- SMSI $0.91
- GDTC $2.21
- Resistance Level
- SMSI $1.09
- GDTC $2.36
- Average True Range (ATR)
- SMSI 0.10
- GDTC 0.13
- MACD
- SMSI -0.00
- GDTC -0.01
- Stochastic Oscillator
- SMSI 24.96
- GDTC 10.55
About SMSI Smith Micro Software Inc.
Smith Micro Software Inc is a provider of software solutions. It develops and markets wireless solutions for wireless service providers, mobile device and chipset manufacturers, and enterprise businesses. It offers multi-platform, modular solutions such as SafePath; CommSuite; and ViewSpot. The company's only reportable segment is Wireless. Its Wireless segment sells to large wireless carriers, cable operators, and OEMs.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.